Lobe Sciences Ltd. (CVE:LOBE) | WebDisclosure

Switch to English

11276	Sociétés
250579	Mots-clés
179215	Articles
136418	Communiqués

Accueil
Sociétés
Lobe Sciences Ltd.

COMMUNIQUÉ DE PRESSE

publié le 18/06/2025 à 05:58, il y a 1 année 4 mois

Lobe Sciences Moves Forward with Development of Conjugated Psilocin(TM) Following April 14 Agreement to Spin Out Compound to Cynaptec Pharmaceuticals
Lobe Sciences Ltd. advances Conjugated Psilocin™ research for chronic cluster headaches and addiction via $6M investment in Cynaptec Pharmaceuticals, with option for additional $20M

Clinical Trials Investment Cynaptec Pharmaceuticals Lobe Sciences Ltd. Conjugated Psilocin™
BRÈVE

publiée le 03/06/2025 à 12:15, il y a 1 année 5 mois

Lobe Sciences Appoints Yong Yao as CFO for Strategic Initiatives

Strategic Growth Operational Expansion Biotech Finance Lobe Sciences Yong Yao
BRÈVE

publiée le 03/06/2025 à 12:15, il y a 1 année 5 mois

Lobe Sciences nomme Yong Yao au poste de directeur financier des initiatives stratégiques

Croissance Stratégique Expansion Opérationnelle Financement Des Biotechnologies Sciences Du Lobe Yong Yao
COMMUNIQUÉ DE PRESSE

publié le 03/06/2025 à 12:10, il y a 1 année 5 mois

Lobe Sciences Appoints Mr. Yong Yao as Chief Financial Officer to Support Strategic Growth
Lobe Sciences Ltd. appoints Mr. Yong Yao as CFO & EVP, leveraging his 25 years of finance & biotech experience to drive financial strategy & growth. Strategic shift to full-time financial leadership

Chief Financial Officer Executive Vice President Finance Strategy Lobe Sciences Yong Yao
BRÈVE

publiée le 14/04/2025 à 13:05, il y a 1 année 6 mois

Lobe Sciences Initiates Private Placement for Drug Development

Private Placement Clinical Trials Lobe Sciences Conjugated Psilocin Cynaptec Pharmaceuticals
BRÈVE

publiée le 14/04/2025 à 13:05, il y a 1 année 6 mois

Lobe Sciences lance un placement privé pour le développement de médicaments

Placement Privé Essais Cliniques Sciences Du Lobe Cynaptec Pharmaceuticals Psilocine Conjuguée
COMMUNIQUÉ DE PRESSE

publié le 14/04/2025 à 13:00, il y a 1 année 6 mois

Lobe Sciences Ltd. Announces Private Placement to Support Drug Development of Novel Conjugated Psilocin(TM)
Lobe Sciences announces US$6M private placement for Cynaptec to fund Conjugated Psilocin development. Option for additional US$20M included. Company focuses on lipid tech for orphan diseases

Private Placement Lobe Sciences Lipid Technology Conjugated Psilocin Cynaptec
BRÈVE

publiée le 05/04/2025 à 05:55, il y a 1 année 6 mois

Lobe Sciences Provides Corporate Update on Recent Transactions

Clinical Trials Convertible Notes FDA Feedback Lobe Sciences Psilocin Mucate
BRÈVE

publiée le 05/04/2025 à 05:55, il y a 1 année 6 mois

Lobe Sciences fournit une mise à jour de l'entreprise sur les transactions récentes

Essais Cliniques Billets Convertibles Commentaires De La FDA Sciences Du Lobe Mucate De Psilocine
COMMUNIQUÉ DE PRESSE

publié le 05/04/2025 à 05:50, il y a 1 année 6 mois

Lobe Sciences Provides Corporate Update
Lobe Sciences provides corporate update on recent transactions and business progress including patents and clinical study results. Focus on lipid technology solutions for medical needs

Corporate Update Recent Transactions Lobe Sciences Lipid Technology Medical Needs

Les Echos

Publié le 04/11/2026 à 18:00, il y a 6 heures 53 minutes

The Belgian State and Engie Group have agreed to extend the target date for concluding the Heads of Terms until 12 December 2026
Publié le 04/11/2026 à 18:00, il y a 6 heures 53 minutes

L’État belge et le groupe ENGIE ont convenu de se donner un délai supplémentaire jusqu’au 12 décembre 2026 pour la conclusion des Heads of Terms
Publié le 04/11/2026 à 17:45, il y a 7 heures 9 minutes

October 2026
Publié le 04/11/2026 à 17:45, il y a 7 heures 9 minutes

Octobre 2026
Publié le 04/11/2026 à 17:44, il y a 7 heures 10 minutes

Aéroports de Paris SA - Information regarding the voting rights and shares as of 31 October 2026

Voir tout LES ECHOS COMFI WIRE

Accesswire

Publié le 04/11/2026 à 23:10, il y a 1 heure 44 minutes

Ur-Energy Announces Date for Third Quarter 2026 Results and Conference Call and Webcast
Publié le 04/11/2026 à 23:00, il y a 1 heure 54 minutes

Avino Reports Q3 2026 Financial Results
Publié le 04/11/2026 à 23:00, il y a 1 heure 54 minutes

Viemed Healthcare Announces Third Quarter 2026 Financial Results
Publié le 04/11/2026 à 22:15, il y a 2 heures 39 minutes

Zomedica Announces Record Third Quarter Revenue of $9.9 Million, Up 22% Year-Over-Year, Net Loss Reduced 48%, with $41 Million in Liquidity
Publié le 04/11/2026 à 22:05, il y a 2 heures 49 minutes

Stabilis Solutions Announces Third Quarter 2026 Results

Voir tout ACCESSWIRE

EQS Group

Publié le 05/11/2026 à 00:02, il y a 51 minutes

EQS-Adhoc: NEXTDC Limited: Response to Share Raid by Goodman Group and Digital Realty
Publié le 04/11/2026 à 19:41, il y a 5 heures 12 minutes

EQS-Adhoc: SNP SE Raises Outlook for the Full Year 2026
Publié le 04/11/2026 à 19:25, il y a 5 heures 28 minutes

Menarini Group and Ryvu Therapeutics Announce First Clinical Data from the Phase II JASPIS-01 Study of dapolsertib (MEN1703, SEL24) in Heavily Pretreated Relapsed/Refractory Aggressive B-cell non-Hodgkin Lymphoma at the 2026 ASH Annual Meeting
Publié le 04/11/2026 à 18:43, il y a 6 heures 10 minutes

EQS-Adhoc: Deutsche EuroShop refines its revenue forecast and raises its earnings forecast for the 2026 financial year
Publié le 04/11/2026 à 18:05, il y a 6 heures 48 minutes

Redis Expands Redis Iris to Give AI Agents the Memory, Context, and Messaging They Need to get to Production